Aytu Biopharma, Inc
AYTU- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001385818
No open-market purchases or sales by Aytu Biopharma, Inc insiders were filed in the last 90 days; 38 institutions reported holding it in 13F filings for Q2 2026, worth $8.25M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Aytu Biopharma, Inc as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 27
- 0 vs. Q1 2024
- Shares held
- 2.05M
- +258.3K (+14.4%) vs. Q1 2024
- Total value
- $5.99M
- +$537.2K (+9.8%) vs. Q1 2024
- New holders
- 3
- 6 more added
- Sold out
- 3
- 6 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AYTU on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 38 | $8.25M |
| Q1 2026 | 37 | $10.7M |
| Q4 2025 | 39 | $9.81M |
| Q3 2025 | 33 | $6.73M |
| Q2 2025 | 32 | $7.45M |
| Q1 2025 | 31 | $2.49M |
| Q4 2024 | 29 | $3.19M |
| Q3 2024 | 24 | $4.81M |
| Q2 2024 | 27 | $5.99M |
| Q1 2024 | 27 | $5.46M |
| Q4 2023 | 22 | $5.02M |
| Q3 2023 | 22 | $4.65M |
| Q2 2023 | 21 | $2.73M |
| Q1 2023 | 21 | $1.21M |
| Q4 2022 | 42 | $1.52M |
| Q3 2022 | 53 | $1.64M |
| Q2 2022 | 41 | $2.50M |
| Q1 2022 | 44 | $6.02M |
| Q4 2021 | 46 | $5.10M |
| Q3 2021 | 49 | $12.2M |
| Q2 2021 | 61 | $26.0M |
| Q1 2021 | 72 | $48.4M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Aytu Biopharma, Inc; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| TSFG, LLC | 1 | $0 | 0.00% | 00.0% | Unchanged |
| CarsonAllaria Wealth Management, Ltd. | 5 | $15 | 0.00% | 00.0% | Unchanged |
| SJS Investment Consulting Inc. | 5 | $15 | 0.00% | +5 | New |
| US Bancorp | 9 | $26 | 0.00% | +9 | New |
| Huntington National Bank | 20 | $58 | 0.00% | 00.0% | Unchanged |
| GWM Advisors LLC | 21 | $61 | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 37 | $108 | 0.00% | 00.0% | Unchanged |
| CIBC Private Wealth Group, LLC | 83 | $242 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 92 | $269 | 0.00% | +42+84.0% | Added |
| Wells Fargo & Company | 124 | $362 | 0.00% | −40−24.4% | Reduced |
| Advisor Group Holdings, Inc. | 300 | $876 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 308 | $899 | 0.00% | −718−70.0% | Reduced |
| Morgan Stanley | 440 | $1.28K | 0.00% | −620−58.5% | Reduced |
| JPMorgan Chase & Co | 540 | $1.57K | 0.00% | −80−12.9% | Reduced |
| Tower Research Capital LLC (TRC) | 1,962 | $5.73K | 0.00% | −1,064−35.2% | Reduced |
| Royal Bank of Canada | 3,285 | $10.0K | 0.00% | +576+21.3% | Added |
| Acadian Asset Management LLC | 14,622 | $41.0K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 14,557 | $42.5K | 0.00% | −70.0% | Reduced |
| Citadel Advisors LLC | 21,810 | $63.5K | 0.00% | +9,635+79.1% | Added |
| BlackRock Inc. | 22,793 | $66.6K | 0.00% | 00.0% | Unchanged |
| Dimensional Fund Advisors LP | 23,551 | $68.5K | 0.00% | +8,311+54.5% | Added |
| Vanguard Group Inc | 27,888 | $81.4K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 35,919 | $104.6K | 0.00% | +1,356+3.9% | Added |
| Renaissance Technologies LLC | 74,123 | $216.4K | 0.00% | +2,800+3.9% | Added |
| Armistice Capital, LLC | 252,000 | $735.8K | 0.02% | +252,000 | New |
| Stonepine Capital Management, LLC | 472,469 | $1.38M | 1.26% | 00.0% | Unchanged |
| Nantahala Capital Management, LLC | 1,086,812 | $3.17M | 0.32% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −13,882−100.0% | Sold out |
| West Financial Advisors, LLC | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −2−100.0% | Sold out |